MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Diurnal wins patent in Europe for Alkindi

StockMarketWire.com

Pharmaceutical group Diurnal said it had been granted a patent for Alkindi by the European Patent Office.

The patent, EP2780003, further expands the company's 'strong exclusivity position for Alkindi in Europe where Diurnal already has 10 years of data and market exclusivity until 2028 through a paediatric use marketing authorisation granted by the European Commission,' the company said.

Alkindi was approved and marketed to treat children suffering from adrenal insufficiency and the related condition congenital adrenal hyperplasia.







Story provided by StockMarketWire.com